Original Research

Page 34

Recently published articles about Original Research

PCC
Burden of Psychiatric Disorders in Moyamoya Disease
Original Research

August 23, 2022

The objective of this study was to investigate psychiatric comorbidities and trends in patients with Moyamoya disease in the United States.
, , , et al
JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
PCC
Suicide Methods of Depressed and Bipolar Individuals
Original Research

August 16, 2022

This study examined the prevalence of different methods of suicide and self-inflicted poisoning/injury in individuals with major depressive disorder or bipolar disorder.
, , , et al
JCP
Intravenous Scopolamine Versus Active Placebo in MDD
Original Research

August 15, 2022

Scopolamine, an agent commonly used for motion sickness, has shown promise in treating depression. This study measured its efficacy in major depressive disorder versus an active placebo comparator.
, , , et al
PCC
Computer Vision Syndrome, Insomnia, and Migraine
Original Research

August 11, 2022

This study assessed the correlation between computer vision syndrome, insomnia, and migraine, using stress as a mediating factor.
, , , et al
JCP
Remission of Psychotic Late-Life Depression Following ECT
Original Research

August 10, 2022

In this study, ECT was associated with a significantly higher remission rate in psychotic versus nonpsychotic late-life depression.
, , , et al
PCC
Substance Abuse and Metabolic Syndrome
Original Research

August 9, 2022

This study estimated the prevalence and predictors of metabolic syndrome among substance users in North India.
, , , et al
JCP
Faces Scales to Measure Anxiety and Anger
Original Research

August 8, 2022

Faces scales are used worldwide to assess pain. This study aimed to develop and evaluate measurement properties of faces scales to monitor the mental health symptoms of anxiety and...
, , , et al
JCP
Very Low-Level Transcranial Photobiomodulation for MDD
Original Research

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...
, , , et al
JCP
Cannabidiol for Treatment-Resistant Anxiety
Original Research

August 3, 2022

Treatment resistance affects nearly half of all young patients experiencing moderate-to-severe anxiety. This study investigated the safety and efficacy of cannabidiol for anxiety in young people who previously failed...
, , , et al
JCP
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics
Original Research

August 3, 2022

This study compared spontaneous reporting of tardive dyskinesia with long-acting injectable versus oral antipsychotics.
, ,
JCP
Add-on Pramipexole for Schizophrenia
Original Research

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe